Want to see HK:9989 full AI Analyst Report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Financial Statements
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Financial Overview
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H's market cap is currently $14.42B. The company's EPS TTM is $0.05; its P/E ratio is 185.14; and it has a dividend yield of 4.22%. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is scheduled to report earnings on April 1, 2027, and the estimated EPS forecast is $0.12. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 5.48B | $ 5.28B | $ 5.45B | $ 7.16B | $ 6.37B |
| Gross Profit | $ 1.74B | $ 1.76B | $ 1.80B | $ 2.33B | $ 2.03B |
| Operating Income | $ 635.97M | $ 741.31M | $ -238.11M | $ 1.14B | $ 773.20M |
| EBITDA | $ 846.59M | $ 1.20B | ― | $ 1.37B | $ 726.64M |
| Net Income | $ 349.49M | $ 646.74M | ― | $ 727.43M | $ 240.79M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.83B | $ 2.56B | $ 2.27B | $ 3.45B | $ 3.93B |
| Total Assets | $ 16.63B | $ 17.34B | $ 19.20B | $ 20.81B | $ 19.11B |
| Total Debt | $ 2.11B | $ 2.98B | $ 3.78B | $ 6.46B | $ 5.65B |
| Net Debt | $ 762.72M | $ 1.29B | $ 1.93B | $ 4.33B | $ 2.71B |
| Total Liabilities | $ 4.55B | $ 5.14B | $ 7.22B | $ 8.41B | $ 7.58B |
| Stockholders' Equity | $ 12.03B | $ 12.15B | $ 11.91B | $ 12.31B | $ 11.41B |
| Cash Flow | |||||
| Free Cash Flow | $ 1.59B | $ 1.99B | $ -46.66M | $ -979.03M | $ -200.49M |
| Operating Cash Flow | $ 1.71B | $ 2.19B | $ 398.22M | $ -756.61M | $ -6.63M |
| Investing Cash Flow | $ -872.75M | $ -415.05M | $ 1.22B | $ 249.84M | $ 719.93M |
| Financing Cash Flow | $ -1.09B | $ -2.14B | $ -1.21B | $ 329.56M | $ -501.08M |
Currency in CNY